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Background: Despite evidence of benefit for pharmacist involvement in chronic disease management, the
provision of these services in community pharmacy has been suboptimal. The Promoting Action on Research
Implementation in Health Services (PARiHS) framework suggests that for knowledge translation to be effective,
there must be evidence of benefit, a context conducive to implementation, and facilitation to support uptake. We
hypothesize that while the evidence and context components of this framework are satisfied, that uptake into
practice has been insufficient because of a lack of facilitation. This protocol describes the rationale and methods of
a feasibility study to test a facilitated pharmacy practice intervention based on the PARiHS framework, to assist
community pharmacists in increasing the number of formal and documented medication management services
completed for patients with diabetes, dyslipidemia, and hypertension.
Methods: A cluster-randomized before-after design will compare ten pharmacies from within a single organization,
with the unit of randomization being the pharmacy. Pharmacies will be randomized to facilitated intervention
based on the PARiHS framework or usual practice. The Alberta Context Tool will be used to establish the context of
practice in each pharmacy. Pharmacies randomized to the intervention will receive task-focused facilitation from an
external facilitator, with the goal of developing alternative team processes to allow the greater provision of medication
management services for patients with diabetes, hypertension, and dyslipidemia. The primary outcome will be a
process evaluation of the needs of community pharmacies to provide more clinical services, the acceptability and
uptake of modifications made, and the willingness of pharmacies to participate. Secondary outcomes will include the
change in the number of formal and documented medication management services in the aforementioned chronic
conditions provided 6 months before, versus after, the intervention between the two groups, and identification of
feasible quantitative outcomes for evaluating the effect of the intervention on patient care outcomes.
Results: To date, the study has identified and enrolled the ten pharmacies required and initiated the intervention process.
Conclusion: This study will be the first to examine the role of facilitation in pharmacy practice, with the goal of scalable
and sustainable practice change.
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The need for pharmacists to play a role in chronic disease
management
Patients with diabetes, dyslipidemia, and hypertension
are not achieving clinical targets as outlined in clinical
practice guidelines [1-6]. It is well established that sub-
optimal control of these conditions increases patients’
risk of major complications such as myocardial infarc-
tion, heart failure, stroke, and kidney disease. As these
conditions are primarily controlled using medications,
adherence to prescribed therapies and appropriate dos-
ing of these therapies become integral in helping to en-
sure patients achieve optimal outcomes.
Recent evidence from a number of systematic reviews
[7-13] suggests that pharmacists’ management of patients’
medications yields improved use of, and adherence to, ther-
apies. Additionally, the recent regulation of pharmacy tech-
nicians in Canada allows them to perform the final check
on dispensed prescriptions [14]. This has created an oppor-
tunity for the greater delegation of this task, thereby freeing
pharmacists to focus more specifically on patient care.
What is holding pharmacists back?
Despite evidence of benefit and greater task flexibility,
pharmacists are not providing medication management to
all eligible patients with chronic conditions. Research into
the reasons for this gap in the treatment of patients points
to a number of barriers including a perceived lack of
knowledge [15], confidence [16], time, and privacy [16,17].
Some work also suggests that pharmacists are tied to trad-
itional dispensing models of practice [15,18,19], and that
the physical environment and workflow of the pharmacy
are mainly dispensing-oriented [20].
Previous research into pharmacy practice change has fo-
cused on encouraging individual practitioners to drive the
change [21], while failing to account for the influence of
organizationally erected barriers within community phar-
macy. A further assumption of this previous research has
been that pharmacists possess the skills needed to identify
and address these barriers, revealing what Rogers has
called an individual-blame bias [22]. Pharmacists across
Canada are interested in providing clinical services to their
patients [18], but previous work in this area has neglected
to provide instruction for how pharmacists can implement
these changes.
The Promoting Action on Research Implementation in
Health Services framework
The Promoting Action on Research Implementation in
Health Services (PARiHS) framework proposes three
interrelated components as part of knowledge transla-
tion strategies: evidence, context, and facilitation [23,24].
Each of these components must be optimized to ensure
the successful implementation of evidence into practiceand share a dynamic and simultaneous relationship with
each other [25]. According to Kitson and colleagues
[23], the most successful implementation occurs when
the following criteria are met:
 Evidence is scientifically robust and matches
professional consensus and patient preferences.
 The context is receptive to change, including
sympathetic workplace culture, strong leadership, and
appropriate monitoring and feedback mechanisms.
 Facilitation is provided to make the change process
easier for group members, with input from skilled
external and internal facilitators.
Study objective/hypothesis
This paper outlines the protocol for a feasibility study of a
facilitated pharmacy practice intervention based on the
PARiHS framework. This intervention is intended to assist
community pharmacists to increase the number of formal
and documented medication management services com-
pleted for patients with diabetes, dyslipidemia, and hyper-
tension, within a medium-to-large retail pharmacy chain
organization. A cluster-randomized design will be utilized,
as the knowledge translation intervention proposed may
result in systemic changes in how pharmacies operate,
thereby increasing the risk of contamination of the control
group if a patient-level randomization were applied.
The objective of the study is to identify the needs of
community pharmacies in implementing clinical services
into practice, explore the acceptability and utility of fa-
cilitation in community pharmacy practice, and conduct
a preliminary analysis on the outcomes of the interven-
tion related to the number of services provided and pa-
tient care outcomes achieved. Should this feasibility
study identify benefit, future work will involve the scale-
up of the intervention across a greater number of phar-
macies, with the ultimate goal of improving clinical care
services provided to patients of community pharmacies.
Methods/design
Design
This will be a feasibility study with a cluster-randomized
before-after design comparing ten pharmacies from within
a single organization, with the unit of randomization as
the pharmacy. Pharmacies will be randomized to facili-
tated intervention, based on the PARiHS framework, or
usual practice in a 1:1 ratio. Ethics approval for the project
has been obtained from the Health Research Ethics Board
at the University of Alberta. Due to the nature of the inter-
vention, blinding is not possible.
Setting
The study will be conducted in community pharmacies
(belonging to the same chain) in the province of Alberta,
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organization to further ensure baseline consistencies
among pharmacies, particularly relating to organizational
structure, policies, and job descriptions.
Participants
Pharmacists
Ten pharmacies belonging to the same pharmacy chain
within the province of Alberta, Canada, will be identified
for participation. Sites must have an interest in, and the
ability to provide, medication management services but
have not fully integrated these activities. No limitations
on prescription count, location, or staffing level were ap-
plied. Rather, pharmacies were contacted and invited to
participate until consent was received from the staff of
ten pharmacies.
Patients
All Alberta residents eligible for the medication manage-
ment services defined below can receive the services and
will be counted towards the study outcomes. Interven-
tion pharmacies will be encouraged to employ case find-
ing strategies [26] to identify possibly eligible patients
with diabetes, hypertension, and/or dyslipidemia. Case
finding strategies use demographic information, as well
as knowledge of condition-specific risk factors and
symptoms to determine whether or not an individual
would benefit from further testing or intervention [26].
By taking this approach to the identification of patient
participants, scarce health resources will be saved as
wholesale screening of the entire population of patients
attending a particular pharmacy will be avoided.
Randomization
The ten participating sites will be matched by an investiga-
tor not involved in enrollment or application of the inter-
vention, into five most similar pairs based on geographic
location, prescription volume, staffing level, and the exist-
ence of any specialty-certified pharmacists (e.g., Certified
Diabetes Educators). However, prescription volume will
form the primary matching variable, as time to conduct
patient care services among other pharmacy activities has
been identified as a key barrier preventing greater per-
formance of these activities in North American pharmacy
practice [27-29]. Using a random-number generator, one
pharmacy from each pair will then be randomly allocated
to either the intervention or control group. All regular
staff of each pharmacy constitutes the members of that
clustered site. Each regular staff member provided in-
formed consent to participate prior to randomization.
Intervention
For the purposes of this project, it will be assumed that
the evidence component of the PARiHS framework forthe value of pharmacists’ intervention in the care of pa-
tients with diabetes, dyslipidemia, or hypertension is suf-
ficiently optimized [7-13] and that pharmacists are
aware of, and support, this evidence [18,30].
External, task-focused facilitation [31], informed by an
evaluation of contextual factors using the Alberta Con-
text Tool (ACT), on-site observations, and participant
interviews, will be applied to train community pharma-
cies to develop alternative team processes that enable a
greater number of medication management services to
be provided to patients with pre-specified chronic condi-
tions [32]. Permissions to utilize the ACT have been re-
ceived. This facilitation process will assist pharmacy
team members in thinking through the change process
and provide them with a set of skills to develop change
strategies in the future. Facilitators will also serve as a li-
aison between management and front-line staff to imple-
ment potential organizational change processes to
ensure alignment between expected service provision
and the operational reality of pharmacy practice.
The facilitation process will begin with an evaluation of
the contexts of all of the pharmacies using the ACT. Then,
baseline rates of the completion of medication manage-
ment services will be measured using pharmacy software.
Facilitated discussions (i.e., participant interviews) will fol-
low with pharmacy team members (managers, pharma-
cists, and technicians) to explore the scores of each of the
dimensions on the ACT, and to develop strategies to ad-
dress any barriers identified. All intervention pharmacy
team members will also be asked to complete a facilitation
evaluation survey.
From this, an alternative team process will be devel-
oped to provide pharmacy teams with guidelines for
how more medication management services could be
completed. These guidelines may include physical layout
considerations, workflow improvements, patient identifi-
cation strategies including case finding [26], task delega-
tion from pharmacists to pharmacy technicians and
assistants [33], and alignment of job description expecta-
tions between front-line staff and management.
Control
Control pharmacies will also complete the ACT, and
baseline rates of the completion of medication manage-
ment services will be collected. However, investigators
will not meet with staff from these locations to discuss
the results of the ACT or provide any assistance with
implementing medication management services. A num-
ber of recent changes affecting the practice of pharmacy
in Alberta, including simplification of the application
process for prescribing authorization [34] and the launch
of programs by advocacy organizations to support apply-
ing pharmacists [35], the regulation of pharmacy techni-
cians [14], and changes to generic drug pricing and
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fore, the use of a concurrent control group aims to iso-
late the effect of the intervention on the outcomes of
interest from these compounding factors.
Outcomes
All outcomes measured will be analyzed at the cluster
level.
Primary outcome
As a feasibility study, process evaluation will form the pri-
mary outcome [37]. Process evaluation will be evaluated
using the comparative baseline results of the ACT [38-40]
for both groups, transcriptions of interviews, field notes,
and the facilitation evaluation surveys [41]. These surveys
will be undertaken pre- and post-intervention and are de-
signed to capture stakeholders’ expectations, and final
thoughts, about the process. Field notes will be kept dur-
ing site visits and all subsequent interactions with the
intervention sites, with the intention of tracking the identi-
fied needs, and implementation of the facilitated interven-
tion. Overall, these data are intended to detail the facilitated
intervention development process to gain insight into the
needs of community pharmacies, the acceptability and up-
take of modifications made, and the willingness of pharma-
cies to participate.
Secondary outcomes
Service provision To gauge the effectiveness of the
intervention in improving medication management ser-
vice provision rates, secondary outcomes will include de-
scriptive analysis of the change in the number of formal
and documented services in the aforementioned chronic
conditions provided 6 months before versus after the
intervention between the two groups. While the defin-
ition of medication management services varies in the
literature, for the purposes of this study, they are defined
as those services currently eligible for remuneration
under the Alberta Pharmacy Services Framework [42]
and include the following:
 Comprehensive Annual Care Plan (CACP)
 Standard Medication Management Assessment
(SMMA)
 Follow-ups to CACP/SMMA
 Assessment and adaptation of a prescription
 Patient assessment for prescription renewal
 Patient assessment in a medication-related emer-
gency (emergency prescribing)
 Optional services (those that can only be provided
by pharmacists with additional certifications):Heart failure
○ Assessment and administration of medications
by injectionIschae○ Patient assessment for initiating medication
therapyFor the purpose of this study, service counts will be
limited to the provision of a CACP, SMMA, or follow-
ups to CACP or SMMA.
A CACP is designed to meet the unique needs of pa-
tients with complex health issues [42]. According to the
Alberta Health Pharmacy Services Framework, ‘complex
needs’ are defined as patients having at least two of the
pre-identified chronic conditions or patients with at least
one pre-identified chronic condition and one pre-
identified risk factor (see Table 1) [42]. A CACP includes
the completion of a patient assessment and a best pos-
sible medication history. This information is then used
to develop a specific care plan to identify and resolve
existing or potential drug-related problems, mutually de-
velop therapy goals, and to follow-up and monitor the
progress on identified goals. All information contained
within the CACP is formally documented and provided
to the patient and any other health professionals in-
volved in the patient’s care, as needed. Prior to conduct-
ing a CACP, informed consent from the patient must be
obtained.
An SMMA is designed to meet the needs of patients
who do not qualify for a CACP [42]. In particular, pa-
tients must have at least one of the pre-specified
chronic conditions and be taking at least three different
Schedule 1 (prescription) medications or insulin, have
diabetes and be taking at least one Schedule 1 drug or
insulin, or use a tobacco product daily and be willing to
receive tobacco cessation services. Steps for completing
and documenting a SMMA are the same as those for
a CACP. Patients having either a CACP or SMMA com-
pleted are eligible for follow-up interactions as required
and outlined in the care plan developed with the
pharmacist [42].Identification of feasible patient care outcomes
With the ultimate goal of improving patient care, this
study also aims to identify feasible clinical outcomes
for collection and analysis, including changes inmic heart disease
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and dyslipidemia management as recorded on applic-
able patients’ follow-up documentation. Potential out-
come measures may include, but are not limited to the
following:
 Glycosylated hemoglobin (HbA1c)
 Fasting plasma glucose
 Systolic and diastolic blood pressure
 Low-density lipoprotein cholesterol (LDL-C)
 High-density lipoprotein cholesterol (HDL-C)
 Triglycerides
 Total cholesterol to HDL-C ratio
Pharmacy staff and management will be consulted to
determine if additional outcomes can be reasonably col-
lected and are relevant for clinical and/or administrative
purposes.
Description of participating pharmacies
To determine the generalizability of this study’s findings
to other pharmacies within the chain and externally, de-
scriptive data on the pharmacies will be identified and
summarized, including location, prescription count, and
staffing level. This data, along with service provision
counts and clinical outcomes, will be utilized in the esti-
mation of the intracluster correlation coefficient.
Data collection
Process evaluation data will be collected over the course
of the study. Results from the ACT will be collected at
baseline and 6 months, as well as results from the facili-
tation evaluation surveys for intervention pharmacies.
Interview data will be collected as they are conducted
through the start-up phase of the intervention, and field
notes will be collected continually as data collection for
the primary outcome begins. All data will be stored se-
curely at the University of Alberta Epidemiology Coord-
inating and Research (EPICORE) Centre.
Data on the change in the number of medication man-
agement services provided will be collected from phar-
macy software programs located within the respective
stores participating. Baseline numbers of medication
management services provided will be counted back
6 months from the time of data collection (for example,
if data collection begins May 1, 2014, pre-intervention
data will be collected starting from November 1, 2013).
Final data regarding the number of medication manage-
ment services provided following the intervention will
be collected for both intervention and control pharma-
cies for 6 months starting after the first set of in-person
visits with the intervention pharmacies.
Data for the secondary clinical outcomes at baseline
and 6 months will be collected at the same time asfollow-up data for the primary outcome, for all patients
receiving CACP or SMMA services. It is of key import-
ance to note that pharmacist participants will not be
asked to complete any data collection for the sole pur-
poses of completion of the study. As the intention of
this project is to improve the sustainability of clinical
intervention provision by pharmacists, it is paramount
that their actions herein are as close as possible to what
they would be performing after the conclusion of the
study. All clinical parameters will be reported by the
pharmacies to the study investigators in aggregate form,
without any patient identifying information. These
values, and the frequency of their collection, will be an-
alyzed descriptively to gauge whether potentially clinic-
ally meaningful changes can be reasonably assessed by
this method.
Statistical analysis
All analyses for the primary and secondary outcomes
will be based on the intention to treat principle. Phar-
macy information, such as average weekly prescription
count or pharmacists with additional certifications, will
be presented descriptively for the purpose of determin-
ing the generalizability of the findings across all pharma-
cies in Alberta.
Results from the interviews, field notes, and the facilita-
tion evaluation surveys will be analyzed for the purposes
of a formative evaluation of the process of implementation
of the facilitated intervention using a grounded theory ap-
proach [43]. In the case of this project, grounded theory is
intended to develop a theory for the process of implemen-
tation of the facilitated intervention within the pilot group
of pharmacies. Data analysis will be an ongoing process, as
the constant comparative analytic technique will be
employed to generate theory and adapt to the needs of the
pharmacies, as the intervention is implemented [43]. The
process evaluation themes identified by Grant et al. [44]
for cluster-randomized trials of complex interventions will
form the basis of this analysis. Facilitators will also track
their time spent interacting with sites and implementing
agreed-upon changes, for the purpose of determining the
feasibility of providing the service to a larger number of
pharmacies for future implementation projects.
We will also include, as part of the feasibility analysis,
estimation of the effect size for the difference in change
in the number of clinical services provided before and
after the intervention between intervention and control
groups, along with confidence interval estimates. This
information, along with the acceptability of the interven-
tion by pharmacies and members of the pharmacy chain
management team and mean amount of facilitator time
required per intervention site, will enable us to deter-
mine whether scale-up of the intervention across the en-
tire chain is feasible, and if the potential costs to employ
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set by increased billing for clinical services from the or-
ganization’s perspective.
Where patients received initial and/or follow-up ser-
vices over the course of the intervention period, counts
of the number, and type of clinical outcomes docu-
mented will be presented, along with mean baseline and
follow-up values for these parameters. Due to the low
sample size of this study and the primary focus on
process outcomes, hypothesis testing on these values will
not be performed.Sample size
For this feasibility study, a pre-determined sample size of
ten pharmacies (five intervention and five control) was de-
cided upon as this was felt to be manageable by a single
volunteer facilitator, and within the budgetary restrictions
of our funding. The enrollment of five intervention sites is
believed to be sufficient to initially detect common systemic
organizational changes that may be of benefit to the phar-
macy chain as a whole, while also allowing for refinement
of the facilitation process for subsequent scale-up efforts.
As the first study of this type in community pharmacies,
the intracluster correlation coefficient (ICC) is unknown. A
cluster-randomized trial of community pharmacies in
Saskatchewan, Canada, estimated an ICC of 0.0143 [45];
however, it must be noted that data utilized to determine
this value originated from various types of pharmacies (i.e.,
department mass-merchandise, chain-franchise, independ-
ent) [46]. One would expect our study to identify a higher
ICC than reported in previous work due to our utilization
of a single pharmacy chain for this study.Discussion
The current pharmacy services funding model [42], and
recent budget cuts [47], mean that it is increasingly im-
portant for pharmacists to demonstrate their value in
improving the care of Albertans. It is well established
that pharmacist-provided care is clinically effective in
improving chronic disease control, but greater provision
of these services in community pharmacies is required.
The intervention outlined in this pilot study offers an
approach to achieving this objective by linking existing
evidence to a scalable and sustained change that will
then be expanded to other pharmacies.Trial status
The study has recruited and enrolled all ten pharmacies
and is currently applying the intervention to the phar-
macies randomized to facilitation. It is anticipated that
the intervention and data collection phases will be com-
pleted in 2015.Abbreviations
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